FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Solomon Jonathan Eitan
 2. Date of Event Requiring Statement (Month/Day/Year)
10/28/2019		 3. Issuer Name and Ticker or Trading Symbol
BiomX Inc. [PHGE]
(Last)
(First)
(Middle)
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NESS ZIONA, L3 7414002		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Options - Right to Buy   (1) 01/07/2027 Common Stock Options 167,434 $ 0.54 D  
Common Stock Options - Right to Buy   (2) 03/26/2027 Common Stock Options 182,133 $ 1.69 D  
Common Stock Options - Right to Buy   (3) 05/22/2028 Common Stock Options 201,718 $ 1.97 D  
Common Stock Options - Right to Buy   (4) 03/29/2029 Common Stock Options 284,701 $ 2.03 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Solomon Jonathan Eitan
C/O BIOMX LTD.
7 PINHAS SAPIR ST., FLOOR 2
NESS ZIONA, L3 7414002		   X     Chief Executive Officer  

Signatures

/s/ Jonathan Solomon 11/05/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 20% of these options vested upon Mr. Solomon's appointment as Chief Executive Officer of BiomX Ltd., a wholly-owned subsidiary of the Issuer, in February 2017. Of the remaining 80%, 25% vested on February 1, 2017, with the remaining options vesting in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 52,316 shares of common stock were unvested.
(2) 25% of these options vested on March 26, 2018. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 68,301 shares of common stock were unvested.
(3) 25% of these options vested on May 22, 2019. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 138,682 shares of common stock were unvested.
(4) 25% of these options shall vest on March 29, 2020. Thereafter, the remaining options shall vest in 12 equal quarterly installments over three years. As of the reporting date, options to purchase 284,701 shares of common stock were unvested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.